The utility of the BANA test for monitoring anaerobic infections due to spirochetes (Treponema denticola) in periodontal disease.
Treponema denticola, Porphyromonas gingivalis, and Bacteroides forsythus each possesses an enzyme(s) that hydrolyzes the synthetic substrate benzoyl-DL-arginine-naphthylamide (BANA). The presence of these organisms in a subgingival plaque sample can be determined by the ability of the plaque to hydrolyze BANA. In the present study, we describe the usefulness of the BANA test at various stages of a clinical trial of the efficacy of metronidazole in the treatment of periodontal disease. A BANA-positive test was significantly associated with high levels and proportions of spirochetes in the plaque, so that it provided information comparable with that which could be obtained by a microscopic examination of the plaque. Patients with such anaerobic spirochetal infections were randomly assigned to a group receiving either metronidazole or placebo (250 mg, three times a day) for one week and whose teeth were scaled and root-planed. The advantages of the decision that metronidazole be used were apparent from the comparison with the results obtained in the patients who received only the scaling and root planing. The initially BANA-positive teeth in the patients treated with metronidazole, scaling, and root planing gained attachment and exhibited a significant reduction in the need for periodontal surgery, when compared with the BANA-positive teeth in the patients who received only placebo, scaling, and root planing. After the conclusion of this therapy, those teeth with persistent BANA-positive plaques had significantly higher proportions and levels of spirochetes than did the teeth with BANA-negative plaques.(ABSTRACT TRUNCATED AT 250 WORDS)
University of Michigan School of Dentistry, Ann Arbor 48109-1078.
W J
WJ
Loesche
J
J
Giordano
P P
PP
Hujoel
D000704:Analysis of Variance; D001587:Benzoylarginine-2-Naphthylamide; D003773:Dental Plaque / Q000382:microbiology; D004311:Double-Blind Method; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D010518:Periodontitis / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D011897:Random Allocation; D012680:Sensitivity and Specificity; D014208:Treponema / Q000032:analysis* / Q000187:drug effects; D014211:Treponemal Infections / Q000175:diagnosis*
D008795:Metronidazole; D001587:Benzoylarginine-2-Naphthylamide